IXICO

Integrating plasma biomarkers with MRI is reshaping Alzheimer's clinical trials. This dual approach improves enrolment precision, reduces screen failures & boosts efficiency.

Read here:
🔗 ixico.com/news-and-res...

James Chandler, Chief Business Officer at IXICO, will be at BIO-Europe in Vienna, Austria, on November 3–5!

If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us

🧠 Happening Tomorrow!
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...

Congratulations to Roche Diagnostics USA on receiving FDA clearance for the Elecsys® pTau181 blood test. The first blood test approved for use in primary care to help rule out Alzheimer’s related amyloid pathology.

diagnostics.roche.com/us/en/news-l...

🧠 IXICO Capital Markets Day
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.

Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.

📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: ir@cavendish.com

Q&A with IXICO CEO Bram Goorden - Vox Markets In this fascinating interview, CEO Bram Goorden of IXICO - an AI powered medical imaging analytics firm - takes me through today’s positive Sept FY’25 trading update alongside yesterday’s 2 impressive...

Our CEO Bram Goorden talks with VOX Market’s Paul Hill about the company’s strong performance in 2025, highlighting above-guidance revenue delivery and continued progress in its strategic focus areas.

▶️ Watch here: www.voxmarkets.co.uk/articles/q-a...

IXICO FY25 trading update now live.

Revenue growth, strengthened cash position, and continued momentum.

Read the full RNS on our website: ixico.com/news-and-res...

New contract + AD trial extension for IXICO.

Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.

🔗 Read more: ixico.com/news-and-res...

1 week to go! Discover how imaging is transforming Alzheimer’s disease clinical trials & uncovering new therapeutic paths.
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST

👉 ixico.com/news-and-res...

How do neuroinflammation & vascular pathology shape Alzheimer’s? Find out Oct 22 in our expert-led webinar.
🔗 ixico.com/news-and-res...

Robin Wolz & Terry Reilly will be at The Michael J Fox Foundations' Parkinson’s Disease Therapeutics Conference on Oct 16.

Catch up with IXICO to explore how imaging & analytics are advancing PD research.

Let’s connect: ixico.com/contact-us

🧠 Tomorrow, we’ll be at ESMRMB2025🧠

Niccolo Fuin and Vahid Malekian will be in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.

Contact us: ixico.com/contact-us

IXICO CEO Bram Goorden will be presenting at the Proactive One2One Investor Forum on 9 October 2025 in London, UK

🔗Find out more www.proactiveinvestors.co.uk/register/eve...

Honoured to be recognised at the Precision Medicine Awards 2025 by Oxford Global for our work in precision neuroscience. Huge thanks to our clients, partners, and the brilliant team behind the scenes.

🧠 We’re attending ESMRMB 2025🧠

Niccolo Fuin and Vahid Malekian will be attending the ESMRMB Annual Meeting in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.

Connect with our team: ixico.com/contact-us

Alzheimer’s is more than amyloid & tau. Join experts on Oct 22 to explore imaging, comorbidities & new targets in AD.
🧠 Register: ixico.com/news-and-res...

Congratulations to Eli Lilly and Company for another milestone in the fight against Alzheimer’s disease receiving EU marketing authorisation for Kisunla (donanemab).

Read more
investor.lilly.com/news-release...

Huge congrats to uniQure, UCL, and all involved in the AMT-130 trial—showing a 75% slowdown in disease progression over 3 years. Incredible work!

Proud to support this trial at IXICO through neuroimaging + analytics. Let’s keep pushing boundaries.

bbc.co.uk/news/article...

🧠IXICO at upcoming scientific congresses 🧠
➡️Niccolo Fuin & Vahid Malekian are attending #ESMRMB in Marseille, 8–11 Oct
➡️Kirsi Kinnunen will be at #ESGCT in Seville, 7–10 Oct,

🧠 Connect with us at both events: ixico.com/contact-us

🧠 Alzheimer’s trial innovation
Join IXICO, Fujirebio & GAP Foundation to explore how blood biomarkers + amyloid PET imaging are transforming AD clinical research.

🎙️ Featuring Robin Wolz, IXICO Chief Scientific & Medical Officer
📅 Oct 9 | 🕒 3:30PM BST / 10:30AM EDT
🔗 events.zoom.us/ev/Apl2Ku3vy...

This #WorldAlzheimersMonth, we joined forces with @GAP_Foundation to spotlight how our collaboration is helping accelerate Alzheimer’s research.
Better access. Faster trials. Meaningful insights. Read more about how we’re making a difference: ixico.com/news-and-res...

World Alzheimer's Disease Awareness Month:
From blood-based biomarkers to gene therapies, Alzheimer’s research is entering a new era—and @‌IXICO is helping lead the way with AI-powered neuroimaging.

📖 Read our latest blog on innovation trends:
🔗 ixico.com/news-and-res...

September is World Alzheimer’s Month, a time to raise awareness and drive change for the 55 million people living with dementia globally—Alzheimer’s accounts for up to 80% of these cases

🔗 ixico.com/therapeutic-...

🎥 ixico.com/news-and-res...

Today IXICO announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications in Alzheimer’s Disease and Friedrich’s Ataxia.

Read more: ixico.com/news-and-res...

IXICO’s latest blog dives into the new wave of research transforming how we diagnose and treat Parkinson’s disease. With breakthroughs in imaging biomarkers and AI-powered analysis, we’re moving closer to truly personalized care.

Blog: ixico.com/news-and-res...

And that’s a wrap at AAIC 2025! Great to see the exponential progress being made by the R&D community towards advancing AD identification and treatment.

Missed us? Let's reconnect -📩 hello@ixico.com

🔗 Learn more about our work in AD: ixico.com/therapeutic-...

We’re here at AAIC 2025!
Catch the poster we’re presenting and meet with us!

🧠 AI-Driven Recruitment for Alzheimer’s Trials
📍Tuesday-464 | 🗓 Tue, Jul 29 |

Let's meet: hello@ixico.com
Learn more: ixico.com/therapeutic-...

🧠 Neurodegeneration imaging is a key talking point as we head to #AAIC2025.

Kirsi Kinnunen breaks it down in her latest blog—worth a read before the conference 👇

🔗 ixico.com/news-and-res...

Catch the IXICO team: Bram, Robin, Terry, Kirsi & Rohan!
Let’s meet: hello@ixico.com

Today IXICO announced it has deepened its existing collaboration with the Global Alzheimer’s Platform Foundation® (GAP) including participation as a neuroimaging partner in the Bio-Hermes-002 study, one of the most prominent global studies in AD research

Read more: ixico.com/news-and-res...

Today IXICO anticipates revenues to be at least £6.3 million, ahead of expectations and representing a 9% increase on 2024 revenues, thereby solidifying its stated return to growth.

Read more:
ixico.com/news-and-res...